Clinical trial
Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
NCT02699879 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 16, 2012
- Completion date
- September 15, 2016
- Enrollment
- 1,009 (actual)
- Sites
- 106
Conditions
As the registry lists them; a condition with its own page is linked.